KDM3A, a Novel Blood-Based Biomarker in Colorectal Carcinogenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Colorectal cancer (CRC) is a major global health concern, necessitating improved diagnostic biomarkers.
• Hypoxia, a low-oxygen state, is linked to CRC progression and involves the Hypoxia-Inducible Factor 1 (HIF-1) pathway.
• KDM3A, a histone demethylase, interacts with HIF-1α, a key component of HIF-1.

Purpose of the Study:

• To investigate the potential of KDM3A gene expression as a predictive biomarker for colorectal cancer.
• To evaluate the correlation between KDM3A, HIF-1α, and Epithelial-Mesenchymal Transition (EMT) gene expression in CRC patients.

Main Methods:

• Quantitative reverse transcription PCR (qRT-PCR) was employed to measure gene expression levels.
• Leukocyte samples were analyzed from 50 colorectal cancer patients across various stages and 50 healthy controls.
• Receiver Operating Characteristic (ROC) curve analysis was performed to assess diagnostic accuracy.

Main Results:

• Significantly higher expression levels of HIF-1α and KDM3A were observed in the CRC group compared to healthy controls.
• Mesenchymal markers, Slug and ZEB-1, also showed significantly higher expression in CRC patients.
• ROC analysis using KDM3A expression yielded an Area Under the Curve (AUC) of 0.664, with 54% sensitivity and 85.4% specificity.

Conclusions:

• KDM3A expression levels are significantly elevated in colorectal cancer patients.
• KDM3A demonstrates potential as a novel supplementary biomarker for CRC diagnosis.
• Noninvasive detection of KDM3A in circulation offers a promising avenue for early CRC detection and management.